$TEVA News

Teva Pharmaceutical Industries (TEVA) Secured WELTRUZA Approval, Is It Still 16% Below Fair Value?

Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Decreased by 19.30% to $0.11

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47

Teva to Host R&D Day on Wednesday, November 11 in New York City

TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament

Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs

FDA approves Teva’s monthly injection of olanzapine for schizophrenia

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Teva climbs premarket as FDA approves once-monthly schizophrenia treatment

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Teva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13